Pilocarpine-induced convulsive activity is limited by multidrug transporters at the rodent blood-brain barrier

The Journal of Pharmacology and Experimental Therapeutics
Kerstin RömermannMarion Bankstahl

Abstract

As a result of the growing availability of genetically engineered mouse lines, the pilocarpine post-status epilepticus (SE) model of temporal lobe epilepsy is increasingly used in mice. A discrepancy in pilocarpine sensitivity in FVB/N wild-type versus P-glycoprotein (PGP)-deficient mice precipitated the investigation of the interaction between pilocarpine and two major multidrug transporters at the blood-brain barrier. Doses of pilocarpine necessary for SE induction were determined in male and female wild-type and PGP-deficient mice. Brain and plasma concentrations were measured following low (30-50 mg⋅kg(-1) i.p.) and/or high (200 mg⋅kg(-1) i.p.) doses of pilocarpine in wild-type mice, and mice lacking PGP, breast cancer resistance protein (BCRP), or both transporters, as well as in rats with or without pretreatment with lithium chloride or tariquidar. Concentration equilibrium transport assays (CETA) were performed using cells overexpressing murine PGP or BCRP. Lower pilocarpine doses were necessary for SE induction in PGP-deficient mice. Brain-plasma ratios were higher in mice lacking PGP or PGP and BCRP, which was also observed after pretreatment with tariquidar in mice and in rats. Lithium chloride did not change brain pe...Continue Reading

References

Mar 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·M TaketoC T Hansen
Mar 1, 1972·Electroencephalography and Clinical Neurophysiology·R J Racine
May 1, 1999·Methods and Findings in Experimental and Clinical Pharmacology·G ChaudharyY K Gupta
Feb 15, 2002·Archives of Neurology·Stephan A MayerBrian-Fred Fitzsimmons
Jul 11, 2002·Brain Research·Carlos A Mejías-AponteAnnabell C Segarra
Jan 16, 2003·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·O A OredipeRajagopalan Sridhar
Apr 18, 2003·Journal of Medicinal Chemistry·Dietmar SchwabJörg Huwyler
May 30, 2003·Pharmacological Reviews·Marilyn E MorrisLisa M Predko
Jun 25, 2003·Experimental Neurology·Karin BorgesRaymond Dingledine
Jun 19, 2004·Journal of Drug Targeting·Remigijus DidziapetrisAlanas Petrauskas
Feb 18, 2005·NeuroRx : the Journal of the American Society for Experimental NeuroTherapeutics·Wolfgang Löscher, Heidrun Potschka
Mar 26, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·David A Lee, Eve J Higginbotham
Jul 19, 2005·Nature Reviews. Neuroscience·Wolfgang Löscher, Heidrun Potschka
Oct 22, 2005·The Journal of Clinical Investigation·John R CirritoDavid M Holtzman
Aug 24, 2006·Toxicology and Industrial Health·Lauren M TetzMadhusoodana P Nambiar
Oct 18, 2006·The Journal of Pharmacology and Experimental Therapeutics·Steffen BaltesWolfgang Löscher
Nov 25, 2006·Brain : a Journal of Neurology·E A van VlietJ A Gorter
Jan 24, 2007·Mammalian Genome : Official Journal of the International Mammalian Genome Society·Melodie R WinawerAbraham A Palmer
Jul 25, 2007·Epilepsia·Nicola MarchiDamir Janigro
Aug 24, 2007·Experimental Neurology·Ina GrötickeWolfgang Löscher
Nov 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nienke A de VriesOlaf van Tellingen
Jun 14, 2008·Journal of Neuroscience Methods·Giulia CuriaMassimo Avoli
Oct 1, 2008·Neuropharmacology·Carlos Luna-TortósWolfgang Löscher
Nov 18, 2008·Neurobiology of Disease·Nicola MarchiDamir Janigro
Jun 6, 2009·The Journal of Pharmacology and Experimental Therapeutics·Ying ChenWilliam F Elmquist
Oct 13, 2009·International Journal of Clinical Practice·V Visvanathan, P Nix
Feb 22, 2012·Behavioural Brain Research·Marion BankstahlWolfgang Löscher

❮ Previous
Next ❯

Citations

Dec 1, 2017·Analytical and Bioanalytical Chemistry·Michiko OyaMakoto Sawada
Apr 27, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Xiao ZhangJianqiang Yu
Dec 12, 2020·The European Journal of Neuroscience·Iman Imtiyaz Ahmed Juvale, Ahmad Tarmizi Che Has
Aug 11, 2020·Heliyon·Iman Imtiyaz Ahmed Juvale, Ahmad Tarmizi Che Has

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood-Brain Barrier Transport in Neurodegeneration

The blood brain barrier is important for regulating the movement of biomolecules in and out of the brain. For example, membrane transporters in the blood brain barrier can be essential for regulating drug movement and dysregulation of these processes may play a role in neurodegeneration. This feed follows the latest research on this topic.

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.